Anticholinergics Linked to Mobility Decline in Seniors

A recent study published in JAMA Network Open highlights a concerning trend regarding the use of anticholinergic medications and their impact on mobility in older adults. The research, conducted by Kaiser Permanente Washington scientists, indicates a significant association between cumulative anticholinergic exposure and faster declines in gait speed and grip strength among this aging population.

Understanding Anticholinergics

Anticholinergic medications are often prescribed to older adults to manage various conditions such as allergies, depression, and gastrointestinal disorders. These drugs work by blocking the action of acetylcholine, a neurotransmitter that plays a crucial role in memory, muscle activation, and overall cognitive function. While these medications have therapeutic benefits, they also come with potential side effects, particularly in older individuals.

Research Methodology

The study analyzed data from 4,283 participants enrolled in the Adult Changes in Thought study spanning from 1994 to 2020. All participants were required to have:

• At least 10 years of continuous health plan enrollment.
• A minimum of two study visits during which gait speed and grip strength were measured.
• An average age between 74.3 to 74.5 years.

Using pharmacy dispensing records, the researchers quantified anticholinergic exposure as total standardized daily doses over 10 years and mean standardized daily doses over two years. This allowed them to develop weighted cumulative exposure models, examining the impact of anticholinergic use over different timeframes (2, 4, 6, 8, or 10 years) on gait speed and grip strength.

Key Findings

The researchers found that:

1. Four-year weighted cumulative exposure provided the best statistical fit, indicating a decline of -0.0034 m/s per year for each 1-unit increase in the weighted mean standardized daily dose of anticholinergic medications.
2. There were no significant associations between conventional exposure measures and grip strength. However, a significant decline in grip strength was noted with six-year weighted cumulative exposure, showing a decrease of -0.0329 kg per year per 1-unit increase in weighted mean standardized daily dose.

Clinical Implications

These findings suggest that higher cumulative anticholinergic use is linked to greater declines in both gait speed and grip strength, independent of aging and comorbidities. The authors stress that even small declines can accumulate and become clinically significant over time. As such, they recommend clinicians to:

• Avoid the prescription of anticholinergic medications whenever possible.
• Prescribe the lowest effective doses.
• Conduct regular evaluations to identify opportunities for deprescribing.

Conclusion

This research underscores the need for heightened awareness regarding the long-term effects of anticholinergic medications on older adults' mobility and physical strength. Given the prevalence of these medications in older populations, it is imperative for healthcare professionals to consider the risks versus benefits when prescribing such treatments.

Further Reading

For more information on the study, you can access the original article titled Cumulative Anticholinergic Exposure and Change in Gait Speed and Grip Strength in Older Adults.

Table of Study Participants

Table of Anticholinergic Exposure Effects

“Accumulation of small losses can become clinically meaningful over time, underscoring the importance of minimizing anticholinergic exposure.” – Shelly L. Gray, Researcher